We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Dupixent Posts Two Wins: Good Data on a Skin Disorder and a New Asthma Indication
Dupixent Posts Two Wins: Good Data on a Skin Disorder and a New Asthma Indication
Sanofi’s and Regeneron Pharmaceuticals’ blockbuster monoclonal antibody Dupixent (dupilumab) gained ground on two fronts last week: an approval for asthma in young children and positive phase 3 trial data for a notoriously difficult-to-treat skin condition with no approved therapy.